Gain Therapeutics, Inc. (GANX)
NASDAQ: GANX · Real-Time Price · USD
2.985
-0.065 (-2.13%)
Mar 9, 2026, 2:02 PM EDT - Market open
Gain Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Revenue | - | - | 0.06 | 0.13 | 0.13 | - | |
| Revenue Growth (YoY) | - | - | -58.40% | -0.96% | - | - | |
| Cost of Revenue | 8.95 | 10.65 | 11.38 | 8.24 | 7.16 | 2.26 | |
| Gross Profit | -8.95 | -10.65 | -11.32 | -8.11 | -7.03 | -2.26 | |
| Selling, General & Admin | 8.65 | 9.71 | 10.93 | 9.68 | 6.84 | 1.25 | |
| Other Operating Expenses | - | - | - | -0.01 | -0.03 | -0.03 | |
| Operating Expenses | 8.65 | 9.71 | 10.93 | 9.68 | 6.81 | 1.22 | |
| Operating Income | -17.59 | -20.36 | -22.26 | -17.79 | -13.84 | -3.48 | |
| Interest & Investment Income | 0.23 | 0.37 | 0.5 | 0.39 | 0.02 | 0 | |
| Currency Exchange Gain (Loss) | -0.73 | 0.12 | -0.43 | -0.1 | -0.07 | -0.1 | |
| Pretax Income | -18.1 | -19.87 | -22.19 | -17.5 | -13.89 | -3.57 | |
| Income Tax Expense | 1.3 | 0.54 | 0.08 | 0.09 | 0 | 0.01 | |
| Net Income | -19.39 | -20.41 | -22.27 | -17.59 | -13.89 | -3.58 | |
| Net Income to Common | -19.39 | -20.41 | -22.27 | -17.59 | -13.89 | -3.58 | |
| Shares Outstanding (Basic) | 30 | 23 | 13 | 12 | 10 | 3 | |
| Shares Outstanding (Diluted) | 30 | 23 | 13 | 12 | 10 | 3 | |
| Shares Change (YoY) | 54.44% | 75.86% | 9.49% | 16.90% | 279.11% | 19.17% | |
| EPS (Basic) | -0.64 | -0.89 | -1.71 | -1.48 | -1.37 | -1.33 | |
| EPS (Diluted) | -0.64 | -0.89 | -1.71 | -1.48 | -1.37 | -1.33 | |
| Free Cash Flow | -17.3 | -18.9 | -18.88 | -14.81 | -12.46 | -3.26 | |
| Free Cash Flow Per Share | -0.57 | -0.83 | -1.45 | -1.25 | -1.23 | -1.22 | |
| Operating Margin | - | - | -40336.86% | -13410.18% | -10332.05% | - | |
| Profit Margin | - | - | -40354.33% | -13262.02% | -10371.70% | - | |
| Free Cash Flow Margin | - | - | -34217.53% | -11166.38% | -9303.42% | - | |
| EBITDA | -17.55 | -20.32 | -22.22 | -17.76 | -13.82 | -3.47 | |
| D&A For EBITDA | 0.04 | 0.04 | 0.04 | 0.03 | 0.02 | 0.01 | |
| EBIT | -17.59 | -20.36 | -22.26 | -17.79 | -13.84 | -3.48 | |
| Revenue as Reported | - | - | 0.06 | 0.14 | 0.16 | 0.03 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.